Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.55 |
| ▸ | CA2 | P00918 | 8/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397963 | 0.87 | CA1 (0.59) | CA1CA2CA9CA4HPRT1 | |
| SCHEMBL7575116 | 0.81 | TK1 (0.59) | HPRT1TK1HSD17B10PNP | |
| SCHEMBL7570078 | 0.81 | TK1 (0.65) | HPRT1TK1ALDH1A1HSD17B10PNP | |
| SCHEMBL7980835 | 0.80 | HPRT1 (0.50) | HPRT1TK1HSD17B10PNP | |
| SCHEMBL7576803 | 0.80 | TK1 (0.60) | HPRT1TK1PNP | |
| SCHEMBL7982329 | 0.80 | TK1 (0.57) | HPRT1TK1HSD17B10PNP | |
| SCHEMBL7567095 | 0.78 | TK1 (0.60) | HPRT1TK1HSD17B10PNP | |
| SCHEMBL7586861 | 0.78 | HINT1 (0.57) | HPRT1TK1ALDH1A1PNP | |
| SCHEMBL7572289 | 0.78 | TK1 (0.60) | HPRT1TK1ALDH1A1HSD17B10PNP | |
| SCHEMBL7567140 | 0.77 | PNP (0.64) | HPRT1TK1ALDH1A1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | claimed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |